Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, talks about the Trial Combining Immunotherapy & Chemotherapy | Survival will be the Primary Endpoint of the Study.
Advertisement
Trial Combining Immunotherapy & Chemotherapy | Survival will be the Primary Endpoint of the Study
By Editor